Wordt geladen...
The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan
BACKGROUND: Elbasvir/grazoprevir (EBR/GZR) is a new generation, fixed‐dose, combination antiviral drug used in chronic hepatitis C virus (HCV) genotype (GT) 1 or 4 infection. Our study evaluates the clinical efficacy and safety of EBR/GZR after its launch in Taiwan. METHODS: This is a retrospective...
Bewaard in:
| Gepubliceerd in: | J Med Virol |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6916308/ https://ncbi.nlm.nih.gov/pubmed/31599455 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.25605 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|